Superantigen antagonist peptides
Open Access
- 1 January 2001
- journal article
- review article
- Published by Springer Nature in Critical Care
- Vol. 5 (2) , 53-55
- https://doi.org/10.1186/cc986
Abstract
The production of superantigenic exotoxins by Gram positive bacteria underlies the pathology of toxic shock syndrome. Future treatment strategies for superantigen-mediated diseases are likely to be directed at blocking the three-way interaction between superantigen, T cell receptor and major histocompatibility class II molecule, which inititates an excessive and disordered inflammatory response. In this article, we review the first published data to address one such strategy in the context of other recognised and experimental treatments.Keywords
This publication has 11 references indexed in Scilit:
- Inhibition of Bacterial Superantigens by Peptides and AntibodiesInfection and Immunity, 2001
- Toxoids of Streptococcal Pyrogenic Exotoxin A Are Protective in Rabbit Models of Streptococcal Toxic Shock SyndromeInfection and Immunity, 2000
- Development of Streptococcal Pyrogenic Exotoxin C Vaccine Toxoids That Are Protective in the Rabbit Model of Toxic Shock SyndromeThe Journal of Immunology, 2000
- Superantigen antagonist protects against lethal shock and defines a new domain for T-cell activationNature Medicine, 2000
- Improved outcome of clindamycin compared with beta-lactam antibiotic treatment for invasive Streptococcus pyogenes infectionThe Pediatric Infectious Disease Journal, 1999
- Molecular analysis of the role of streptococcal pyrogenic exotoxin A (SPEA) in invasive soft‐tissue infection resulting from Streptococcus pyogenesMolecular Microbiology, 1999
- Invasive Group A Streptococcal Infections: T1M1 Isolates Expressing Pyrogenic Exotoxins A and B in Combination with Selective Lack of Toxin‐Neutralizing Antibodies Are Associated with Increased Risk of Streptococcal Toxic Shock SyndromeThe Journal of Infectious Diseases, 1999
- Intravenous Immunoglobulin Therapy for Streptococcal Toxic Shock Syndrome—A Comparative Observational StudyClinical Infectious Diseases, 1999
- Comparative effects of clindamycin and ampicillin on superantigenic activity of Streptococcus pyogenesJournal of Antimicrobial Chemotherapy, 1997
- Plasma from patients with severe invasive group A streptococcal infections treated with normal polyspecific IgG inhibits streptococcal superantigen-induced T cell proliferation and cytokine production.The Journal of Immunology, 1996